Effectiveness of infliximab in the treatment of refractory perineal cutaneous Crohn disease.
Geyer
A S
AS
Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA.
Anhalt
G J
GJ
Nousari
H C
HC
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003424:Crohn Disease / Q000150:complications*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D005260:Female; D006099:Granuloma / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D000069285:Infliximab; D007275:Injections, Intravenous; D008875:Middle Aged; D010502:Perineum; D012883:Skin Ulcer / Q000188:drug therapy* / Q000209:etiology; D013997:Time Factors
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab